FDA Inspection 653973 — Celgene Corporation

Celgene Corporation — FEI 3004991673

The FDA completed an inspection of Celgene Corporation on Mar 19, 2010 in Summit, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 4 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Mar 19, 2010
Fiscal Year
2010
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Summit, NJ (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
194221 CFR 211.180(e)Records reviewed annually
357221 CFR 211.100(b)Procedure Deviations Recorded and Justified
361621 CFR 211.165(d)Acceptance criteria for sampling & testing

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.